Treatment of HIV infection: Swedish recommendations 2009

Filip Josephson, Jan Albert, Leo Flamholc, Magnus Gisslen, Olof Karlstrom, Lars Moberg, Lars Naver, Veronica Svedhem, Bo Svennerholm, Anders Sonnerborg

    Research output: Contribution to journalReview articlepeer-review

    16 Citations (SciVal)


    On 4 previous occasions, in 2002, 2003, 2005 and 2007, the Swedish Medical Products Agency (Lakemedelsverket) and the Swedish Reference Group for Antiviral Therapy (RAV) have jointly published recommendations for the treatment of HIV infection. In November 2008, an expert group under the guidance of RAV once more revised the guidelines, of which this is a translation into English. The most important updates in the present guidelines include the following: (a) treatment initiation is now recommended at a CD4 cell count of approximately 350/mu l; (b) new recommendations for first-line therapy: abacavir/lamivudine or tenofovir/emtricitabine in combination with efavirenz or a boosted protease inhibitor (PI/r); (c) an increased focus on reducing the use of antiretroviral drugs that may cause lipoatrophy; (d) an emphasis on quality assurance of HIV care through the use of InfCare HIV; (e) considerably altered recommendations for the initiation of antiretroviral therapy in children. All infants (<1 y) should start antiretroviral therapy, regardless of immune status. Also, absolute CD4+ cell counts, rather than percentage, may be used to guide treatment initiation in children above the age of 5 y.
    Original languageEnglish
    Pages (from-to)788-807
    JournalScandinavian Journal of Infectious Diseases
    Issue number11-12
    Publication statusPublished - 2009

    Subject classification (UKÄ)

    • Infectious Medicine


    Dive into the research topics of 'Treatment of HIV infection: Swedish recommendations 2009'. Together they form a unique fingerprint.

    Cite this